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SUMMARY 
New serological tests for Chlamydia trachomatis (Ct) present promising options to 
improve understanding of Ct epidemiology and prevention. Ct serology offers a 
means of investigating Ct incidence and may be developed as a biomarker of 
scarring disease. Serological assays therefore have potential as epidemiological 
tools to quantify unmet need, inform service planning and evaluate interventions 
including Ct screening, treatment and new vaccine candidates. However, questions 
about their performance characteristics and interpretation remain, which must be 
addressed to advance development in this field. In this personal view, we explore the 
current state of knowledge related to Ct serology and propose several priority 
actions. These are: i) development of ‘target product profiles’ to guide assay 
selection and evaluation across multiple applications and populations; ii) 
establishment of a serum bank to facilitate assay development and evaluation and iii) 
development of technical and statistical methods for assay evaluation and analysis 
of serological findings.  
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Introduction 
There has been substantial investment over the last decade in public health 
programmes to control both genital1 and ocular2 infection with Chlamydia 
trachomatis (Ct). However, several important questions about Ct epidemiology, the 
most effective means of control, and optimum models of surveillance remain.3-5 
Given ongoing control efforts, and the promise of Ct vaccines on the horizon,6 robust 
methods are needed to allow monitoring of and insight into Ct prevalence, 
incidence,7 and the progression to scarring sequelae. Measures of current infection 
based on DNA/RNA detection provide a limited understanding of these features of Ct 
infection. Alternative approaches are therefore required, and in recent years we have 
seen a revival in the use of Ct serology in the fields of genital chlamydia and 
trachoma.  
 
Methods to detect Ct antibodies in serum have been available for several decades.8 
However, use of Ct serology has been hampered by cross-reactivity with other 
chlamydia species,9 suboptimal sensitivity of many assays,10,11 an incomplete 
understanding about the longevity and clinical implications of Ct antibodies and the 
relationship between Ct infection and antibody response.10 Consequently, chlamydia 
seroepidemiology fell out of widespread use among researchers and funding bodies 
for several years. Following the development of novel, sensitive and more specific Ct 
serologic assays,12-16 there is now growing interest in the use of Ct serology as an 
epidemiological tool. For example, assays have been developed with capability to 
detect antibodies against a range of Ct antigens, lateral flow assays are being 
evaluated for field use and dried blood spots have been used to facilitate specimen 
collection, transport and storage (Table 1). 
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Our understanding of mucosal immunity and Ct immunology suggest that urogenital 
and ocular infections with Ct lead to detectable IgG response using appropriate 
serological assays in the majority of confirmed infections.12-14,17   Several factors 
affect the magnitude of response and the ability of serological tests to detect a 
previous infection, including the target antibody, the assay used, time since infection 
and patient characteristics such as age, sex, race and prior Ct infection.12,13,15,18 In a 
UK-based study that compared several assays in the same population, the sensitivity 
to detect a previous known infection ranged from 46% (Medac) to 83% (Pgp3 
double-antigen) in women and 40% (SeroCT) to 54% (Pgp3 double-antigen) in men 
when compared to a previous Ct diagnosis by NAAT.12,14 Seroreversion (loss of 
detectable antibodies) has been demonstrated in some cases but varies by infection 
history and assay,18 with minimal loss of detectable antibody reported in one study 
using a double-antigen Pgp3 ELISA.14 In a study of Ct seroprevalence in the context 
of mass azithromycin treatment for trachoma prevention in a high prevalence area, 
no instances of seroreversion were observed after six months.19 Ct serological tests 
can therefore be used to measure age-specific cumulative incidence,10,20 albeit 
representing a lower bound estimate due to potentially incomplete seroconversion 
and loss of detectable antibodies over time. Ct antibody response has also been 
found to correlate with known history of scarring sequelae, with antibody titres found 
to be higher in those with tubal factor infertility21 and detection of specific antibodies 
being more common in those with known disease.22 Thus, serological assays may 
also offer the promise of use as a biomarker of disease.  
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Given the imperfect sensitivity of serological tests, Ct serology has limited diagnostic 
value; in the absence of genetic diagnostic methods it is an accepted tool for 
presumptive diagnosis of lymphogranuloma venereum (LGV),23 yet is not utilized for 
diagnosis of other biovars. The real potential value of Ct serology is instead in the 
realm of surveillance. Similar to the use of HIV antibody tests within recent infection 
test algorithms (RITA) to support and monitor recent HIV infection,24 Ct serology is 
unlikely to aid in the diagnosis or management of Ct infection. However, it may prove 
invaluable in monitoring history of Ct exposure to inform resource allocation and 
possible clinical need as well as the impact of population-based interventions.   
 
In this personal view, we explore the potential public health applications of Ct 
serology, discuss key challenges of using Ct serology in these ways and finally 
propose priorities for research and development to progress the field. This work grew 
out of an expert meeting convened by Public Health England in 2016 and 
subsequent discussions, and has been supplemented by a rapid review of the 
literature, using searches of two electronic databases (MEDLINE and EMBASE, see 
Table 1). We hope that our collective thoughts help create a direction for research 
and programmatic activities for this exciting field. 
 
Public health applications of Chlamydia trachomatis serology 
Ct serology provides a means of quantifying the prevalence and incidence of Ct 
infection. A more thorough understanding of population-level Ct prevalence and 
incidence is critical to identify unmet need for screening and treatment services and 
to evaluate the impact of Ct control interventions. Obtaining reliable estimates of 
these measures is, however, challenging. In the case of genital chlamydia, the 
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majority of Ct infections are asymptomatic and increases in screening leads to 
increases in reported diagnoses.25  As a result, surveillance is often based on case-
based reporting alone with no or limited information on numbers tested, which is 
believed to produce a gross underestimate of the true population level of disease.25 
Furthermore, comparability between countries is limited by differences in testing 
recommendations, performance characteristics of diagnostic tests, and reporting 
policies and practices.26 Even where testing denominators are available, interpreting 
positivity as a measure of prevalence is difficult as the tested population has a 
different underlying risk from the general population.25,27 Few countries have 
undertaken surveys of prevalence in general population samples and where surveys 
have been done,28-30 they were resource intensive and are unlikely to be feasible in 
many settings.  
 
Ct seroprevalence as a marker of cumulative incidence has been used in several 
countries14,20,31-34 as a means of exploring Ct epidemiology and in some cases to 
investigate population impact of control interventions. In the field of trachoma, mass 
drug administration (MDA) programmes have been hugely successful in reducing Ct 
infection and Ct-related ocular disease.35-37 Longitudinal Ct serology monitoring has 
strong potential as a tool for post-elimination surveillance,38-40 and so provides an 
opportunity to evaluate programme effectiveness and possibly a further 
understanding of the public health response needed in countries where trachoma 
has not been eliminated.41 With suitable statistical approaches, Ct serology has the 
potential to be used to measure annual incidence of Ct (at any site of infection) using 
repeated, cross-sectional measurement over time (Ades, personal communication) 
or to detect step changes in exposure by birth-cohort expected in the context of 
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control measures.38,42 Distinguishing between recent and past or longstanding 
infections would also help to inform understandings of incidence and methods are 
already being developed to enable the use of Ct serology in this manner.43 
 
The second potential application of Ct serology is as a measure of Ct-related 
disease, such as pelvic inflammatory disease (PID) or ectopic pregnancy (EP). As 
the ultimate goal of Ct control is to reduce incidence of disease, monitoring 
biomarkers of disease (and not just infection) would allow an improved 
understanding of whether Ct control is leading to a reduction in reproductive 
sequelae, even in the absence of substantial reductions in transmission. A Ct-
specific biomarker of disease would be especially useful, because Ct is not the only 
cause of long-term reproductive complications such as PID, EP, and tubal factor 
infertility (TFI), and because Ct-related conditions may occur many years after the 
causative infection.44 Measures of the proportion of long-term sequelae that are 
attributable to Ct infection (the ‘population excess fraction’) are also essential to 
determine the need for, and cost-effectiveness of, control interventions.  
 
Serological methods have been used to investigate the relationship between Ct 
infection and sequelae and to estimate the proportion of long-term sequelae 
attributable to genital Ct infection.21,45-48 Novel approaches also offer some promise 
in this area. For example, Ades et al have developed a method using finite mixture 
modelling of antibody titre to estimate the population excess fraction of TFI caused 
by chlamydia.21 Additionally, proteomic arrays are also being explored as a means of 
identifying ‘serological fingerprints’ to indicate the presence of disease related to 
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genital Ct infection (personal communication, Katrin Hufnagel, DKFZ) and scarring 
following ocular infection.49 
 
The third potential application of Ct serology is in the development and evaluation of 
Ct vaccines. The need for an effective Ct vaccine has been set out in the joint WHO-
NIH STI vaccine roadmap.50 Substantial progress towards a Ct vaccine has been 
made in recent years, with candidate vaccines now in the preclinical and clinical 
testing phases.6 Several ‘priority action areas’ set out in the roadmap may be 
addressed through serology. These include obtaining better epidemiological data, 
improving understanding of the natural history of Ct and burden of sequelae, 
expediting clinical development and evaluation and encouraging investment in Ct 
vaccine development. Specifically, Ct serology could be used to obtain more 
complete and precise estimates of the global burden of Ct-associated sequelae, 
which are critical for establishing the public health rationale for vaccination and for 
potential investors who need to assess the likely impact of investing in any 
successful vaccine candidate.6  
 
When a safe vaccine candidate does come to Phase III clinical trial, there is also a 
clear role for serology in identifying Ct-naïve participants for recruitment and for 
developing vaccination strategies through an understanding of age-specific 
exposure. Vaccine evaluation would also benefit from a biomarker of tubal damage 
for use as part of a clinical endpoint for assessing vaccine efficacy, given current 
diagnostic inaccuracy for Ct-related outcomes such as PID.44 The time and 
resources needed to power a clinical trial of candidate Ct vaccines with PID or TFI as 
outcomes may also be prohibitive. It is not yet clear whether serology will be able to 
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provide such a marker, perhaps in combination with cellular markers or radiologic 
findings, but this is an important area of interest given the need for such measures in 
any future vaccine evaluation. As Ct infections (with the exception of LGV) are 
localised in the columnar epithelium, detection of antibodies from genital secretions 
has been proposed as a means of investigating correlates of immune protection 
against Ct,17 which may complement serological investigations. Assessing vaccine-
induced immune responses will depend on the vaccine’s mechanism of action. 
Assays that distinguish between natural and vaccine-induced antibody response will 
therefore be needed.    
 
Key challenges to the use of Ct serology in Public Health 
While progress has been made in recent years, there remain some important 
challenges within the field of Ct serology that need to be addressed to improve the 
utility and value of these methods in a public health context. Interpreting Ct 
seroprevalence is not straightforward. Complexities include that: not everyone 
exposed to Ct will become infected; some individuals with Ct infection will not 
necessarily develop antibodies; women are more likely to develop detectable 
antibodies than men following urogenital Ct infection;12,20,51 Ct antibodies are not 
infection-site (i.e. ocular/urogenital) specific; and seroprevalence can vary with 
number of previous infections and time since infection (as antibodies develop or 
wane).18 These complexities require careful consideration when planning studies and 
undertaking statistical analysis. However, we imagine many of these limitations will 
bias estimates of Ct seroprevalence to the same degree over time, allowing for 
particular utility in monitoring trends over time. 
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Assay sensitivity and specificity determination in the absence of an agreed-upon 
gold standard is also a challenge. Careful consideration of the application and 
population in which a test is to be used will be needed when selecting negative and 
positive controls and determining assay thresholds. For example, studies exploring 
previous Ct infection versus a specific Ct-associated complication may dictate 
different analytic needs in terms of sensitivity and specificity and choice of controls. 
Choice of thresholds for distinguishing Ct ‘positive’ from ‘negative’ antibody 
responses in different populations presents a further challenge, as assays may be 
affected by differences in cross-reactivity and background antibody levels, which can 
vary (e.g. by country and/or ethnicity).  
 
The relative performance of different tests cannot easily be determined without 
evaluation against the same reference sera. Some laboratory-developed assays 
have been compared to commercial assays or other laboratory-developed 
assays,12,14,52,53 but there is relatively little data available to show how different 
assays perform within the same population. In order to establish performance 
characteristics of assays for different applications and populations, large numbers of 
sera which are well-characterised in terms of clinical and demographic information 
are needed. Serum collections from previous studies (e.g. HPV vaccine trials,54 HIV 
unlinked anonymous testing55) or residual samples from clinical testing31 could be of 
use, but these often have limited clinical or demographic information, and varying 
access arrangements mean that assays have not been evaluated on comparable 
samples. 
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Optimal test characteristics for one application may vary from those needed in 
another, meaning that different characteristics may be prioritised. For example, a test 
to measure if someone has had Ct infection will need to detect antibodies that persist 
over time at relatively low levels with high specificity. However, a test which is used 
to estimate the population excess fraction would ideally be able to distinguish 
between complicated and uncomplicated Ct infections (e.g. by identifying high 
versus low levels of antibody in serum,21 subclass of antibody,13 or antibodies 
specifically associated with complications22).  
 
Similarly, the context in which an assay is to be deployed will influence prioritisation. 
For example, in a research setting, tests could be more operator-intensive and less 
cost-effective than tests used for ongoing surveillance given limited government 
budgets. Furthermore, a test requiring high volume of sera may be acceptable in a 
setting where additional blood can be collected from consenting patients whereas 
surveillance systems relying on leftover sera from routine testing may have a limited 
volume available. Applications in a surveillance context may be more tolerant to 
some reduced precision than if used within a vaccine trial, where previous infection 
needs to be ruled out to precisely define populations for efficacy analysis.  
 
Next Steps 
In order to address the challenges set out above, we propose a number of actions to 
address these research and development priorities as follows:  
 
1. Generate target product profiles for Ct serological tests 
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Target product profiles (TPPs) originated in the field of drug development as a 
means of focussing discussions between regulatory authorities and research 
sponsors. They allow the drug development process to be directed with the end goal 
in mind so that both patient and market needs are met.56 The process of establishing 
TPPs is now widespread in drug and vaccine development and their use has also 
extended into the field of diagnostics, for example for tuberculosis57 and point of care 
diagnostics for STI.58  
 
TPPs for Ct serological tests should establish the minimal and optimal assay 
requirements for the different applications described above. Table 2 sets out some of 
the initial considerations that can be used to inform TPPs. A TPP requires broad 
technical consultation across clinical, microbiological and epidemiological science, 
representation from vaccine and diagnostic development companies, research 
groups, public health agencies and funders.  
 
2. Establish a serum bank of adequate and well-characterised sera, with 
standardised clinical outcome assessment and epidemiological data and 
appropriate access arrangements.  
A well-defined serum bank with the evaluation of Ct serology in mind will be an 
invaluable resource. The value of serum banks in infectious diseases research was 
recently set out in an editorial in the Lancet.59 The development of a Ct-specific 
serum bank would facilitate clear and fair access to specimens and relevant 
epidemiologic and clinical data (i.e. age, sex, Ct diagnosis history). A serum bank 
would have enormous potential to support development and evaluation of serological 
assays, and to facilitate identification of potential vaccine targets and correlates of 
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protection. The bank should include sera from women and men of a variety of 
countries, ages and ethnicities with a range of characteristics, including: varying 
histories of Ct diagnosis, incorporating individuals with varying time since treatment 
and numbers of known infections; those with and without reproductive complications; 
exposure to potentially cross-reactive pathogens such as C. pneumoniae; and from a 
range of populations across the world. Some applications such as identifying 
biomarkers of scarring sequelae, or developing serological test to distinguish 
between infection and exposure may also benefit from simultaneous assessment of 
cellular immunity. Thus, collections that incorporate both serum and whole blood 
specimens would be particularly valuable, although would require different regulatory 
permissions in some settings and would incur additional expense arising from 
arrangements for collection and storage.  
 
3. Develop methods for assay evaluation and analysis of serological findings. 
Shared protocols to guide assay evaluation will allow for comparability of estimates 
using Ct serological methods across assays and increase consistency of reporting. 
Evaluation protocols should incorporate a consensus position on optimum methods 
of estimating sensitivity and specificity of Ct serological assays, and recognise the 
need for selection of controls and assay thresholds to be determined according to 
the intended application while also considering the potential for cross-reactivity. 
Future efforts should also focus on development and application of statistical 
methods to appropriately analyse Ct serological findings. 
 
Summary & conclusion 
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As reported Ct rates remain high or continue to rise in many developed countries, Ct 
serology holds much promise in several areas of public health and is already being 
used to gain further insight into Ct epidemiology and natural history. We explored the 
current state of knowledge related to Ct serology and identified several priority 
actions that we believe would directly benefit public health and advance knowledge 
within the Ct field (Panel 1).  
 
As public health agencies continue to be pressed to address rates of Ct and the 
considerable accompanying morbidity arising from infections, a more data-driven 
approach to programmatic decision making at the country, state, and municipality 
level is critical.  Promising interventions, including vaccines, do and will need robust 
measures for estimating the at-risk population and determining the potential impact 
of prevention measures.  Ct serology holds much promise as an additional public 
health tool to help better understand populations at risk for Ct and develop novel and 
effective interventions. 
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Panel 1: Research priorities to further develop the public health applications of 
Chlamydia trachomatis serological assays 
1. Generate target product profiles (TPP) for Ct serological assays.  
• What are the minimal/optimal characteristics of Ct serological assays for different 
purposes (design and evaluation of genital Ct control programmes; design and 
evaluation of trachoma/ocular Ct control programmes; vaccine development and 
evaluation) and measures (seroprevalence Ct antibodies as a measure of Ct 
prevalence and incidence; measure of population excess fraction of disease, e.g. 
PID, tubal factor infertility; biomarker of disease, alone or in combination with other 
measures; measure of being Ct-naïve; measure of vaccine-induced immune 
response)? 
• What are the minimal/optimal characteristics for the above purposes and measures 
in different countries?  
 
2. Establish a serum bank  
• To include adequate volumes of well-characterised sera from women and men who 
have and have not had Ct infection of a variety of ages (including children who may 
still have maternal antibody) and ethnicities, with a range of characteristics including: 
number of known infections, time since treatment and presence of known 
reproductive tract/ocular complications. 
• To incorporate standardised clinical outcome assessment and epidemiological data. 
• Established with appropriate access arrangements. 
 
3. Develop methods for assay evaluation and analysis of serological findings 
• How should sensitivity and specificity be estimated for different purposes? 
• How should positive and negative controls be selected for different test applications? 
• What assay thresholds should be used for each assay for different applications/test 
settings? 
• How should head to head comparison studies be carried out? 
• What statistical methods should be used for measuring epidemiological parameters 
(e.g. incidence, population excess fraction)? 
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Table 1: Chlamydia trachomatis serological assays* 
Assays/group Platform/format Antigen(s) (antibody class/subclass 
detected) 
Examples of public health applications to date* 
  Measure 
seroprevalence/ 
estimate incidence 
Investigate 
association with 
disease 
Evaluate control intervention(s) 
Genital Ct Trachoma 
ELISAs       
Wills et al12 Indirect ELISA Pgp3 (IgG) ⃝20  ⃝20  
Horner et al14 Double-antigen ELISA Pgp3 (IgG, IgA, IgM) ⃝14,20,34  ⃝20  
Winstanley et al15  Indirect ELISA Pgp3 (IgG)     
Albritton et al17 Indirect ELISA  Elementary bodies (EBs) from Ct serovars 
D/UW3/Cx and E/UW5/Cx (IgG, IgA) 
 ⃝17   
Menon et al60 Multi-peptide indirect ELISA 12-mer peptides derived from HtrA, hsp60 
and Ct44361 (IgG) 
 ⃝60,62   
Migchelsen et al35 Indirect ELISA on dried blood 
spots 
Pgp3 (IgG) ⃝35,63    
Geisler et al13 Indirect ELISA Ct EBs of serovars D/UW-3, F/ICCal-13, 
and J/UW-36 (IgG1, IgG3) 
⃝13,64  ⃝45,48   
Commercially available65-67 ELISA/EIA MOMP, hsp60 (IgG, IgA) ⃝32,33,68 ⃝46,48,69-75   
Multiplex bead arrays       
Goodhew et al16 Multiplex bead array Pgp3, CT694 (IgG, IgA) ⃝16   ⃝38-40,76 
Willhauck-Fleckenstein et al77 Multiplex bead array MOMP A/D/L2, PorB, TARP, hsp60-1, Pgp3 
(IgG, or IgG, IgA, IgM) 
    
Near-patient testing       
Gwyn et al52 Lateral flow Pgp3 (IgG, IgA, IgM) ⃝52,53    
Whole proteome microarray       
Lu et al78  Whole proteome microarray Representing 908 genomic and plasmid 
ORFs of Ct strain D/UW3 (IgG, IgA, IgM) 
 ⃝49,78   
Hufnagel et al79 Whole proteome microarray Representing 895 proteins of Ct strain 
D/UW-3/Cx (IgG, or IgG, IgA, IgM) 
 ⃝79   
Budrys et al22 ELISA-based proteome array Representing 908 proteins of Ct strain 
D/UW-3/Cx (IgG) 
 ⃝22   
       
Immunofluorescence       
Chernesky et al80 Whole cell inclusion 
immunofluorescence (WIF) 
L2 serovar (IgG, IgA, IgM)  ⃝21,81   
Commercially-available82,83 Micro-immunofluorescent 
assay (MIF) 
Ct EBs of serovars D-K (IgG, IgA, IgM)  ⃝84   
Wang85 Modified MIF protocol Ct EBs (IgG) ⃝86 ⃝87   
       
*Assays listed are provided as examples within the assay type and examples of public health applications to date are included; the absence of a study does not indicate absence of potential use; 
this is not intended to be a comprehensive review. Assays and studies were identified by participants of the expert meeting, including newly-developed assays presented at the ESCR 2016 meeting 
and a subsequent search of Embase and Pubmed from September 2016 using the terms ‘Chlamydia trachomatis’, ‘serology’ and ‘antibodies’ to identify emerging evidence and applications. Ct, 
Chlamydia trachomatis; EB, elementary body; ELISA, enzyme-linked immunosorbent assays; EIA, enzyme immunoassay; HtrA, high temperature requirement A protease; MOMP, major outer 
membrane protein; TARP, translocated actin-recruiting phosphoprotein; hsp60, heat shock protein 60; ORF, open reading frame.
 19 
 
Table 2: Considerations for different applications of Chlamydia trachomatis 
serological assays 
 
Measuring infection Measuring disease 
For use in vaccine 
evaluation 
Performance 
requirements 
High sensitivity and 
specificity in relation to 
infection. 
 
Ability to distinguish first 
from repeat infection and 
ability to measure recent 
infection would be 
beneficial. 
 
Monitoring and surveillance 
applications could likely 
tolerate lower precision than 
needed for vaccine studies. 
Able to distinguish between 
complicated and 
uncomplicated infections. 
 
Relies on identifying 
disease-specific antigens or 
combinations of antigens  
AND/OR 
Magnitude of response 
associated with disease. 
 
High specificity for sequelae 
to prevent over-investment 
in resource poor 
environments arising from 
over-estimation of the 
incidence of Ct sequelae. 
 
To quantify burden of 
infection/disease 
As for measuring 
infection/disease  
 
For determining Ct-naïve 
status for trials 
High precision  
High sensitivity 
Distinguish between exposure 
and infection 
 
For vaccine efficacy 
measurement 
Marker of tubal involvement 
potentially in combination with 
other measures (e.g., cellular 
markers, radiologic measures) 
would be valuable. 
Marker of vaccine-induced 
immune response will depend 
on mechanism of action of 
vaccine; will need to 
distinguish vaccine-induced vs 
natural responses. 
Dependencies Appropriate panel(s) of 
population-based sera. 
To estimate disease 
incidence 
Appropriate panel(s) of 
population-based sera. 
 
To estimate PEF 
Availability of reliable cases 
and controls with clear case 
definition. 
Vaccine trial design.  
Mechanism of action of 
vaccine candidate. 
Statistical 
method 
considerations 
Establishing Ct serological 
assay threshold/cutoffs 
appropriate to the 
application and population.  
 
Relationship between 
seroprevalence and 
cumulative/annual 
incidence needs 
consideration of impact of 
time since infection and 
repeat infections on Ct 
antibodies. 
Establishing 
threshold/cutoffs 
appropriate to the 
application and population. 
Establishing threshold/cutoffs 
appropriate to the application 
and population. 
Technical 
requirements 
High throughput, low 
volume, and low resource 
utilization methods would 
be valued. 
Monitoring and surveillance 
applications would value 
high throughput, low 
volume, and low resource 
utilization methods. 
 
Research applications may 
tolerate methods requiring 
higher specimen 
volume/operator intensive 
methods. 
Could likely tolerate methods 
requiring higher specimen 
volume/ operator intensive 
methods. 
Ct: Chlamydia trachomatis; PEF: population excess fraction (the proportion of long-term 
sequelae that are attributable to Ct infection)
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